Chitra Sridar

713 total citations
17 papers, 567 citations indexed

About

Chitra Sridar is a scholar working on Pharmacology, Oncology and Pharmacology. According to data from OpenAlex, Chitra Sridar has authored 17 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 8 papers in Oncology and 5 papers in Pharmacology. Recurrent topics in Chitra Sridar's work include Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (7 papers) and Computational Drug Discovery Methods (3 papers). Chitra Sridar is often cited by papers focused on Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (7 papers) and Computational Drug Discovery Methods (3 papers). Chitra Sridar collaborates with scholars based in United States, Australia and Switzerland. Chitra Sridar's co-authors include Paul F. Hollenberg, Ute M. Kent, J. Andrew Williams, Theunis C. Goosen, Natasha T. Snider, Jaime D’Agostino, Thomas J. Feuerstein, James M. Rae, Matthew J. Sikora and Elizabeth M. J. Gillam and has published in prestigious journals such as The FASEB Journal, Biochemical and Biophysical Research Communications and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Chitra Sridar

17 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chitra Sridar United States 12 334 136 122 114 72 17 567
Víctor Pérez-Álvarez Mexico 13 369 1.1× 177 1.3× 82 0.7× 72 0.6× 98 1.4× 30 844
Olajide E. Olaleye China 18 319 1.0× 324 2.4× 125 1.0× 82 0.7× 36 0.5× 25 791
Timothy J. Strelevitz United States 9 402 1.2× 237 1.7× 88 0.7× 248 2.2× 24 0.3× 13 722
Evan Smith United States 9 255 0.8× 130 1.0× 61 0.5× 95 0.8× 34 0.5× 13 490
Chuan Li China 21 404 1.2× 451 3.3× 151 1.2× 156 1.4× 45 0.6× 49 1.1k
Bok-Ryang Kim South Korea 14 316 0.9× 351 2.6× 105 0.9× 241 2.1× 36 0.5× 16 814
Eriko Koyama Japan 15 305 0.9× 171 1.3× 107 0.9× 167 1.5× 18 0.3× 18 798
Loren Berry United States 13 237 0.7× 284 2.1× 86 0.7× 132 1.2× 35 0.5× 20 694
Mika Kurkela Finland 17 515 1.5× 362 2.7× 107 0.9× 227 2.0× 20 0.3× 37 915
Nancy Eddy Hopkins United States 17 434 1.3× 306 2.3× 50 0.4× 197 1.7× 28 0.4× 25 905

Countries citing papers authored by Chitra Sridar

Since Specialization
Citations

This map shows the geographic impact of Chitra Sridar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chitra Sridar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chitra Sridar more than expected).

Fields of papers citing papers by Chitra Sridar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chitra Sridar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chitra Sridar. The network helps show where Chitra Sridar may publish in the future.

Co-authorship network of co-authors of Chitra Sridar

This figure shows the co-authorship network connecting the top 25 collaborators of Chitra Sridar. A scholar is included among the top collaborators of Chitra Sridar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chitra Sridar. Chitra Sridar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Yoshigae, Yasushi, Chitra Sridar, Ute M. Kent, & Paul F. Hollenberg. (2013). The Inactivation of Human CYP2E1 by Phenethyl Isothiocyanate, a Naturally Occurring Chemopreventive Agent, and Its Oxidative Bioactivation. Drug Metabolism and Disposition. 41(4). 858–869. 24 indexed citations
2.
Sridar, Chitra, Jaime D’Agostino, & Paul F. Hollenberg. (2012). Bioactivation of the Cancer Chemopreventive Agent Tamoxifen to Quinone Methides by Cytochrome P4502B6 and Identification of the Modified Residue on the Apoprotein. Drug Metabolism and Disposition. 40(12). 2280–2288. 41 indexed citations
3.
Sridar, Chitra, et al.. (2012). Inhibition of Bupropion Metabolism by Selegiline: Mechanism-Based Inactivation of Human CYP2B6 and Characterization of Glutathione and Peptide Adducts. Drug Metabolism and Disposition. 40(12). 2256–2266. 21 indexed citations
4.
Sridar, Chitra, Imad Hanna, & Paul F. Hollenberg. (2012). Quantitation of UGT1A1 in human liver microsomes using stable isotope-labelled peptides and mass spectrometry based proteomic approaches. Xenobiotica. 43(4). 336–345. 12 indexed citations
5.
Calinski, Diane, Haoming Zhang, Chitra Sridar, & Paul F. Hollenberg. (2012). Metabolism of Cyclophosphamide by the Human Cytochrome P450 2B6 Polymorphic Variants. The FASEB Journal. 26(S1). 2 indexed citations
6.
Sridar, Chitra, Natasha T. Snider, & Paul F. Hollenberg. (2011). Anandamide Oxidation by Wild-Type and Polymorphically Expressed CYP2B6 and CYP2D6. Drug Metabolism and Disposition. 39(5). 782–788. 46 indexed citations
7.
8.
Snider, Natasha T., Matthew J. Sikora, Chitra Sridar, et al.. (2008). The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6. Journal of Pharmacology and Experimental Therapeutics. 327(2). 538–545. 79 indexed citations
9.
10.
Kent, Ute M., et al.. (2008). Modification of Serine 360 by a Reactive Intermediate of 17-α-Ethynylestradiol Results in Mechanism-Based Inactivation of Cytochrome P450s 2B1 and 2B6. Chemical Research in Toxicology. 21(10). 1956–1963. 10 indexed citations
11.
Sridar, Chitra, et al.. (2006). Synthesis of Substituted Phenyl Diaziridines and Characterization as Mechanism-Based Inactivators of Human Cytochrome P450 2B6. Drug Metabolism and Disposition. 34(11). 1849–1855. 8 indexed citations
12.
Kobayashi, Yoshimasa, Chitra Sridar, Ute M. Kent, et al.. (2006). Structure-Activity Relationship and Elucidation of the Determinant Factor(s) Responsible for the Mechanism-Based Inactivation of Cytochrome P450 2B6 by Substituted Phenyl Diaziridines. Drug Metabolism and Disposition. 34(12). 2102–2110. 3 indexed citations
13.
Bumpus, Namandjé N., Chitra Sridar, Ute M. Kent, & Paul F. Hollenberg. (2005). THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION. Drug Metabolism and Disposition. 33(6). 795–802. 33 indexed citations
14.
Sridar, Chitra, et al.. (2005). Roles of the threonine 407, aspartic acid 417, and threonine 419 residues in P450 2B1 in metabolism. Biochemical and Biophysical Research Communications. 338(1). 386–393. 2 indexed citations
15.
Weymarn, Linda B. von, Chitra Sridar, & Paul F. Hollenberg. (2004). Identification of Amino Acid Residues Involved in the Inactivation of Cytochrome P450 2B1 by Two Acetylenic Compounds: The Role of Three Residues in Nonsubstrate Recognition Sites. Journal of Pharmacology and Experimental Therapeutics. 311(1). 71–79. 11 indexed citations
16.
Sridar, Chitra, Theunis C. Goosen, Ute M. Kent, J. Andrew Williams, & Paul F. Hollenberg. (2004). SILYBIN INACTIVATES CYTOCHROMES P450 3A4 AND 2C9 AND INHIBITS MAJOR HEPATIC GLUCURONOSYLTRANSFERASES. Drug Metabolism and Disposition. 32(6). 587–594. 156 indexed citations
17.
Sridar, Chitra, Ute M. Kent, L. Notley, Elizabeth M. J. Gillam, & Paul F. Hollenberg. (2002). Effect of Tamoxifen on the Enzymatic Activity of Human Cytochrome CYP2B6. Journal of Pharmacology and Experimental Therapeutics. 301(3). 945–952. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Víctor Pérez-Álvarez Breakdown of academic impact, for papers by Olajide E. Olaleye Breakdown of academic impact, for papers by Timothy J. Strelevitz Breakdown of academic impact, for papers by Evan Smith Breakdown of academic impact, for papers by Chuan Li Breakdown of academic impact, for papers by Bok-Ryang Kim Breakdown of academic impact, for papers by Eriko Koyama Breakdown of academic impact, for papers by Loren Berry Breakdown of academic impact, for papers by Mika Kurkela Breakdown of academic impact, for papers by Nancy Eddy Hopkins
Rankless by CCL
2026